MAPT and Alzheimer disease: Previously reported biochemical correlates of cognitive decline in PD include lower levels of cerebrospinal fluid (CSF) amyloid beta, specifically the disease-implicated form of amyloid beta known as Aβ42 [22,23], and lower levels of plasma epidermal growth factor (EGF) [24,25], while higher levels of CSF total tau (t-tau) and phosphorylated tau (p-tau) associate with poorer cognition in Alzheimer disease (AD) [23].